14.50
1.26%
0.18
Handel nachbörslich:
14.56
0.06
+0.41%
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? - Pharmaceutical Technology
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) to Post FY2024 Earnings of ($0.68) Per Share, William Blair Forecasts - MarketBeat
Dr. Thomas Casale discusses the impact of type 1 allergies and new treatments - KOKH FOX25
GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray) - Business Wire
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 2.5% - MarketBeat
(SPRY) Technical Data - Stock Traders Daily
Nasal spray for severe allergies now available in the US By Investing.com - Investing.com Canada
Nasal spray for severe allergies now available in the US - Investing.com
ARS Pharmaceuticals updates manufacturing agreement terms - Investing.com
Nasal spray for severe allergies now available in the US - Investing.com India
ARS Pharmaceuticals Announces U.S. Availability of neffy® - GlobeNewswire
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis - Marketscreener.com
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis - StockTitan
Bank of New York Mellon Corp Increases Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) PT Raised to $25.00 - MarketBeat
Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $140,000.00 in Stock - MarketBeat
Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals exec sells over $1.29 million in company stock By Investing.com - Investing.com South Africa
Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com South Africa
Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com Canada
Ars pharmaceuticals exec sells $140,000 in company stock - Investing.com
ARS Pharmaceuticals exec sells over $1.29 million in company stock - Investing.com India
Ars Pharmaceuticals CEO sells over $1.29 million in company stock - Investing.com India
Ars Pharmaceuticals CEO sells over $1.29 million in company stock - Investing.com
Ars pharmaceuticals exec sells $140,000 in company stock By Investing.com - Investing.com UK
ARS Pharmaceuticals exec sells over $1.29 million in company stock - Investing.com
Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com Canada
ARS Pharmaceuticals exec sells over $1.29 million in company stock By Investing.com - Investing.com UK
Ars Pharmaceuticals CEO sells over $1.29 million in company stock By Investing.com - Investing.com UK
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 3.1% - MarketBeat
Merino closer to Arsenal debut - Tribal Football
Recent Insider Activity Could Benefit ARS Pharmaceuticals Inc (SPRY) - Knox Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down to $13.30 - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Receives Overweight Rating from Cantor Fitzgerald - Defense World
Should investors be concerned about ARS Pharmaceuticals Inc (SPRY)? - US Post News
ARS Pharmaceuticals (NASDAQ:SPRY) Rating Reiterated by Cantor Fitzgerald - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why - MSN
Investors in cash trouble should check out ARS Pharmaceuticals Inc (SPRY) - SETE News
Ares Management raises over $3.3B of U.S. opportunistic real estate capital (NYSE:ARES) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $22.75 Consensus PT from Brokerages - MarketBeat
Quest Partners LLC Increases Holdings in Resideo Technologies, Inc. (NYSE:REZI) - Defense World
ARS Pharmaceuticals Inc [SPRY] stock for 1,149,775 USD was sold by Tanimoto Sarina - Knox Daily
How To Trade (SPRY) - Stock Traders Daily
ARS Pharmaceuticals Inc: Navigating a Turbulent Year, Up -23.45% from 52-Week Low - The InvestChronicle
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow - Simply Wall St
There is no way ARS Pharmaceuticals Inc (SPRY) can keep these numbers up - SETE News
ARS Pharmaceuticals (SPRY): A Bull Case Theory - Yahoo Finance
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - StockTitan
ARS Pharmaceuticals Inc (SPRY) did well last session? - US Post News
ARS Pharma seeks FDA nod for needle-free epinephrine By Investing.com - Investing.com Australia
ARS Pharma seeks FDA nod for needle-free epinephrine - Investing.com
ARS Pharma seeks FDA nod for needle-free epinephrine By Investing.com - Investing.com Canada
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I - The Bakersfield Californian
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg - GlobeNewswire
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) - StockTitan
Analyst Ratings For ARS Pharmaceuticals - Benzinga
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat
Analytical Lens: Exploring ARS Pharmaceuticals Inc (SPRY)’s Financial Story Through Ratios - The Dwinnex
Insider Returns Down To US$660k As ARS Pharmaceuticals' Stock Dips 12% - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why - Yahoo Finance
ARS Pharmaceuticals Stock: A Decent Bet For Upside After Neffy Approval (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals Launches Pre-Ordering Services for - GlobeNewswire
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First - The Bakersfield Californian
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis - StockTitan
Short Interest in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expands By 21.6% - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 2.9% - MarketBeat
Leerink Partnrs Comments on ARS Pharmaceuticals, Inc.'s Q4 2024 Earnings (NASDAQ:SPRY) - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):